Authors

Giuseppe Giaccone, MD, PhD

Latest:

Dr. Giaconne on the Lack of Funding for Rare Cancers Research

Giuseppe Giaccone, MD, PhD, highlights the difficulties with funding for research focused on rare cancers.

Coral Olazagasti, MD

Latest:

Dr Olazagasti on Disparities in Lung Cancer Screening Rates for Hispanic Head and Neck Cancer Survivors

Coral Olazagasti, MD, discusses disparities in lung cancer screening rates between Hispanic and non-Hispanic White survivors of head and neck cancer.

Amy DeZern, MD, MHS

Latest:

Closing Thoughts on the MDS Treatment Landscape

Following its comprehensive discussion on the treatment of MDS, the expert panel concludes with thoughts on the overall treatment landscape.

Polly Niravath, MD

Latest:

Dr Niravath on Durvalumab, Trastuzumab, and Pertuzumab in HER2-Enriched Breast Cancer

Polly Niravath, MD, discusses a chemotherapy-free regimen of durvalumab, trastuzumab, and pertuzumab in HER2-enriched early breast cancer.

Timothy Gershon, MD, PhD

Latest:

Dr Gershon on Deep Responses With Mirdametinib in NF1-PN

Timothy Gershon, MD, PhD, discusses an analysis of patients with NF1-PN who achieved deep responses with mirdametinib in the phase 2b ReNeu study.

Ranjit S. Bindra, MD, PhD

Latest:

Dr Bindra on the Role of MGMT Loss on Resistance Mechanisms in Cancer

Ranjit S. Bindra, MD, PhD, discusses a new class of DNA modifiers which selectively target tumor DNA with the goal of overcoming resistance mechanisms across multiple types of cancer.

Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center

Latest:

Sequencing Later-Line Therapies for Metastatic Urothelial Carcinoma

A brief review of second-line and subsequent treatment strategies in metastatic urothelial carcinoma and novel therapies being explored in this space.

Howard M. Ross, MD

Latest:

Dr. Ross on the Role of the Microbiome in CRC

Howard M. Ross, MD, discusses the role of the microbiome colorectal cancer.

Mili Arora, MD

Latest:

In the Trenches With the Fellows

Mili Arora, MD, talks about changing the fellowship program at UC Davis, the effect the COVID-19 pandemic has had on her trainees, and the importance of working late nights with her fellows.

Carl M. Gay, MD, PhD

Latest:

SCLC: Future Therapies and Advice to Community Oncologists

Drs Carl M. Gay and Jared Weiss highlight several novel strategies that show promise in optimizing treatment for patients with small cell lung cancer and respond to questions from community oncologists who manage treatment for patients with lung cancer.

Stephan Stilgenbauer, MD, Ulm University

Latest:

Novel Treatment Combinations in Chronic Lymphocytic Leukemia

Dr Brown and Dr Stilgenbauer provide their input on novel treatment options emerging for chronic lymphocytic leukemia.

Rutika J. Mehta, MD, MPH

Latest:

Dr. Mehta on the Current Treatment Paradigm in HER2-Positive Gastric Cancer

Rutika J. Mehta, MD, MPH, discusses the current treatment paradigm in HER2-positive gastric cancer.

Tracy T. Batchelor, MD, MPH

Latest:

Dr Batchelor on the Rationale for Investigating Tirabrutinib in PCNSL

Tracy T. Batchelor, MD, MPH, discusses the rationale for investigating tirabrutinib for the treatment of patients with primary central nervous system lymphoma.

Susan O’Brien, MD

Latest:

Novel Strategies in Managing Patients With High-Risk Chronic Lymphocytic Leukemia

Key opinion leaders provide their perspective on the optimal management of high-risk chronic lymphocytic leukemia with novel therapeutic agents.

Amado J. Zurita-Saavedra, MD

Latest:

Dr. Zurita-Saavedra on Augmenting Therapy Earlier in Prostate Cancer Treatment Journey

Amado J. Zurita-Saavedra, MD, discusses the potential benefits of augmenting therapy earlier on in the treatment of patients with newly diagnosed metastatic prostate cancer.

Virginia Kaklamani, MD

Latest:

Multidisciplinary Treatment Sequencing and Coordination

Panelists discuss their approach to sequencing surgery, radiation, and systemic therapies for early-stage breast cancer patients, emphasizing the guiding principles of treatment sequencing and how individual patient factors influence decisions; they also highlight the importance of multidisciplinary coordination, identifying key specialists, ensuring alignment on diagnosis, risk assessment, and treatment goals, and the critical role of including the patient in these discussions.

Isabella C. Glitza Oliva, MD, PhD, MS

Latest:

Dr. Glitza Olivia on the Potential Utility of Pembrolizumab/Selinexor in Advanced Melanoma

Isabella C. Glitza Oliva, MD, PhD, MS, discusses the potential utility of pembrolizumab in combination with selinexor in advanced melanoma.

Shridar Ganesan, MD, PhD

Latest:

Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care

Shridar Ganesan, MD, PhD, discusses the current limitations and advantages of leveraging circulating-tumor DNA to detect minimal residual disease in patients with cancer, as well as how ctDNA assays may address mechanisms of resistance in clinical practice.

Niloy Jewel J. Samadder, MD

Latest:

Examining the Promise of Multicancer Early Detection Tests: Looking to the Future

In this seventh episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss the data that are still needed to inform optimal utilization of multicancer early detection tests and their potential cost effectiveness.

Vivek Subbiah, MD

Latest:

Implementing In-House Biomarker Testing: Rationale and Key Considerations

Panelists discuss how implementing in-house biomarker testing can significantly enhance patient care through faster turnaround times and streamlined decision-making processes. This approach reduces dependence on external laboratories while enabling more immediate clinical interventions. Key implementation considerations include staff expertise, quality control protocols, equipment costs, regulatory compliance, and testing volume to ensure operational efficiency and return on investment